Neurologic Stem Cell Treatment Study

Last updated: May 5, 2025
Sponsor: MD Stem Cells
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hemorrhage

Traumatic Brain Injury

Dementia

Treatment

Intravenous and Intranasal BMSC

Clinical Study ID

NCT02795052
MDSC-NEST
  • Ages > 18
  • All Genders

Study Summary

This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Have documented functional damage to the central or peripheral nervous systemunlikely to improve with present standard of care.

  2. Be at least 6 months post-onset of the disease.

  3. If under current medical therapy (pharmacologic or surgical treatment) for thecondition be considered stable on that treatment and unlikely to have reversal ofthe associated neurologic functional damage as a result of the ongoing pharmacologicor surgical treatment.

  4. In the estimation of Dr. Weiss and the neurologists have the potential forimprovement with BMSC treatment and be at minimal risk of any potential harm fromthe procedure.

  5. Be over the age of 18 and capable of providing informed consent.

  6. Be medically stable and able to be medically cleared by their primary care physicianor a licensed primary care practitioner for the procedure. Medical clearance meansthat in the estimation of the primary care practitioner, the patient can reasonablybe expected to undergo the procedure without significant medical risk to health.

Exclusion

Exclusion Criteria:

  1. All patients must be capable of an adequate neurologic examination and evaluation todocument the pathology. This will include the ability to cooperate with the exam.

  2. Patients must be capable and willing to undergo follow up neurologic exams with thesub-investigators or their own neurologists as outlined in the protocol.

  3. Patients must be capable of providing informed consent.

  4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present asignificant risk of harm to the patient's general health or to their neurologicfunction. .

  5. Patients who are not medically stable or who may be at significant risk to theirhealth undergoing the procedure will not be eligible.

  6. Women of childbearing age must not be pregnant at the time of treatment and shouldrefrain from becoming pregnant for 3 months post treatment.

Study Design

Total Participants: 500
Treatment Group(s): 1
Primary Treatment: Intravenous and Intranasal BMSC
Phase:
Study Start date:
June 01, 2016
Estimated Completion Date:
July 31, 2027

Study Description

Various clinical studies have registered with the National Institutes of Health (NIH) to study neurologic diseases and damage. There have also been a number of journal reports of the benefits of treatment with BMSC for diseases and damage to nervous tissue. The investigators hope to add to the volume of literature regarding the use of BMSC in those neurologic diseases and conditions identified as likely to respond to this treatment.

Intravenous administration of BMSC is a well-established approach to neurologic disease and injury with much support for its effectiveness in the pre-clinical and clinical literature. BMSC and the associated bone marrow fraction are posited to have a number of different mechanisms by which they may potentially improve neurologic function. In regards their ability to penetrate the blood-brain barrier for potential neuronal transdifferentiation and direct impact on the neurons and glial tissue within the brain, it should be remembered that within the diencephalon there are specific circumventricular organs which lie in the wall of the third ventricle. These are noteworthy for a significantly diminished blood-brain barrier and glial limitans which facilitates their function of coordinating homeostatic mechanisms of the endocrine and nervous systems. Therefore the investigators believe entry of BMSC may be facilitated in this area of the brain.

The NEST Study provides a treatment Arm 1 which combines intravenous BMSC with topical application of BMSC to the lower 1/3 of the nasal passages as a means of introducing BMSC to the Central Nervous System (CNS). This is applied bilaterally to the inferior nasal conchas and meatuses. The Trigeminal Nerve or 5th Cranial Nerve is a paired, large sensory and motor nerve with multiple branches. It provides sensation to the surface and interior structures of the face including the nasal mucosa that lines the nose. The nerves of the Trigeminal Nerve providing sensation to this area converge and enter the brain at the level of the pons. There is documentation in the scientific literature that intranasal delivery of BMSC allows the BMSC to follow the pathways of the trigeminal nerve, facilitating entry into the parenchyma and cerebral spinal fluid (CSF) for effects on the CNS.

Connect with a study center

  • MD Stem Cells Kobinia Med

    Vienna, 1010
    Austria

    Active - Recruiting

  • Fakeeh University Hospital

    Dubai Silicon Oasis, Dubai
    United Arab Emirates

    Site Not Available

  • Fakeeh University Hospital

    Dubai Silicone Oasis, Dubai
    United Arab Emirates

    Site Not Available

  • Medcare Orthopaedics & Spine Hospital

    Dubai,
    United Arab Emirates

    Active - Recruiting

  • The Saudi-German Hospital

    Dubai, 337-1500
    United Arab Emirates

    Active - Recruiting

  • MD Stem Cells

    Westport, Connecticut 06880
    United States

    Active - Recruiting

  • MD Stem Cells

    Coral Springs, Florida 33065
    United States

    Active - Recruiting

  • The Healing Institute

    Margate, Florida 33063
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.